Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2009

01-06-2009 | NON-THEMATIC REVIEW

Osteosarcoma treatment: state of the art

Authors: Hang T. Ta, Crispin R. Dass, Peter F. M. Choong, Dave E. Dunstan

Published in: Cancer and Metastasis Reviews | Issue 1-2/2009

Login to get access

Abstract

Osteosarcoma (OS) is a class of cancer originating from bone, mainly afflicting children or young adults. It is the second highest cause of cancer-related death in these age groups, mainly due to development of often fatal metastasis, usually in the lungs. Survival for these patients is poor despite the aggressive use of surgery, chemotherapy, and/or radiotherapy. Thus, new effective drugs and other forms of therapy are needed. This article reviews the biology and the state of the art management of OS. New experimental drugs and potential therapies targeting molecular pathways of OS are also discussed.
Literature
1.
Unni, K. K. (1996). Dahlin’s bone tumors: General aspects and data on 11,087 cases. Philadelphia: Lippincott-Raven.
2.
3.
4.
Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treatment Reviews, 32, 423–436.PubMedCrossRef
5.
Quan, G. M. Y., Ojaimi, J., Nadesapillai, W. A. P., Zhou, H., & Choong, P. F. M. (2002). Resistance of epiphyseal cartilage to invasion by osteosarcoma of antiangiogenic factors. Pathobiology, 70, 361–367.PubMedCrossRef
6.
Whelan, J. (2005). Advances in osteosarcoma. In T. O. B. Eden, et al. (Eds.), Cancer and the adolescent (pp. 113–120). Malden: Blackwell.CrossRef
7.
Dass, C. R., Ek, E. T., Contreras, K. G., & Choong, P. F. (2006). A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clinical and Experimental Metastasis, 23, 367–380.PubMed
8.
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist, 9, 422–441.PubMedCrossRef
9.
Clark, J. C. M., Dass, C. R., & Choong, P. F. M. (2007). A review of clinical and molecular prognostic factors in osteosarcoma. Journal of Cancer Research Clinical Oncology, 134, 281–297.CrossRef
10.
Rytting, M., Pearson, P., & Raymond, A. K. (2000). Osteosarcoma in preadolescent patients. Clinical Orthopaedics, 373, 39–50.CrossRef
11.
Fraumeni, J. F. (1967). Stature and malignant tumors of bones in childhood and adolescence. Cancer, 20, 967–973.PubMedCrossRef
12.
Grimer, R. J. (2005). Osteosarcoma and surgery. In T. O. B. Eden, et al. (Eds.), Cancer and the adolescent (pp. 121–132). Malden: Blackwell.CrossRef
13.
Withrow, S. J., Powers, B. E., Straw, R. C., & Wilkins, R. M. (1991). Comparative aspects of osteosarcoma. Dog versus man. Clinical Orthopaedics and Related Research, 270, 159–168.PubMed
14.
Tjalma, R. A. (1966). Canine bone sarcoma: estimation of relative risk as a function of body size. Journal of the National Cancer Institute, 36, 1137–1150.PubMed
15.
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2004). Stature of young people with malignant bone tumors. Pediatric Blood and Cancer, 42, 59–63.PubMedCrossRef
16.
Gelberg, K. H., Fitzgerald, E. F., Hwang, S., & Dubrow, R. (1997). Growth and development and other risk for osteosarcoma in children and young adults. International Journal of Epidemiology, 26, 272–278.PubMedCrossRef
17.
Longhi, A., Pasini, A., Cicognani, A., Baronio, F., Pellacani, A., & Baldini, N. (2005). Height as a risk factor for osteosarcoma. Journal of pediatric hematology/oncology, 27, 314–318.PubMedCrossRef
18.
Longhi, A., Barbieri, E., & FAbbri, N. (2003). Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing’s sarcoma. Tumorigenesis, 89, 569–572.
19.
Picci, P. (2007). Osteosarcoma (Osteogenic sarcoma). Orphanet Journal of Rare Diseases, 2, 1–4.CrossRef
20.
Fuschs, B., & Pritchard, D. J. (2002). Etiology of osteosarcoma. Clinical orthopaedics, 397, 40–52.CrossRef
21.
Wang, L. L., Gannavaparu, A., & Kozinets, C. A. (2003). Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. Journal of the National Cancer Institute, 95, 669–674.PubMed
22.
Finkel, M. P., Biskis, B. O., & Jinkins, P. B. (1966). Virus induction of osteosarcomas in mice. Science, 151, 698–701.PubMedCrossRef
23.
Fuchs, B., & Pritchard, D. J. (2002). Etiology of osteosarcoma. Clinical Orthopaedics, 397, 40–52.CrossRef
24.
Kakar, S., Mihalov, M., Chachlani, N. A., Ghosh, L., & Johnstone, H. (2000). Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma. Journal of surgical oncology, 73, 125–126.PubMedCrossRef
25.
Mendoza, S. M., Konishi, T., & Miller, C. W. (1998). Integration of SV40 in human osteosarcoma DNA. Oncogene, 17, 2457–2462.PubMedCrossRef
26.
Engels, E. A. (2005). Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research. Expert Review of Vaccines, 4, 197–206.PubMedCrossRef
27.
Franchi, A., Arganini, L., & Baroni, G. (1998). Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high grade osteosarcomas. Journal of pathology, 185, 284–289.PubMedCrossRef
28.
Huvos, A. (1991). Bone tumors: Diagnosis, treatment and prognosis. Philadelphia: Saunders.
29.
30.
Wittig, J. C., Bickels, J., Priebat, D., Jelinek, J., Kellar-Graney, K., Shmookler, B., et al. (2002). Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. American Family Physician, 65, 1123–1132.PubMed
31.
Link, M. P., Goorin, A. M., Horowitz, M., Meyer, W. H., Belasco, J., Baker, A., et al. (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clinical Orthopaedics and Related Research, 270, 8–14.PubMed
32.
Hannisdal, E., Solheim, O. P., Theodorsen, L., & Host, H. (1990). Alterations of blood analyses at relapse of osteosarcoma and Ewing’s sarcoma. Acta oncologica, 29, 585–587.PubMedCrossRef
33.
Bacci, G., Longhi, A., Ferrari, S., Lari, S., Manfrini, M., Donati, D., et al. (2002). Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncology reports, 9, 171–175.PubMed
34.
Bacci, G., Longhi, A., Ferrari, S., Briccoli, A., Donati, D., Paolis, M. D., et al. (2004). Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: Experience at Rizzoli on 1421. Tumorigenesis, 90, 478–484.
35.
Aisen, A. M., Martel, W., Braunstein, E. M., McMillin, K. I., Phillips, W. A., & Kling, T. F. (1986). MRI and CT evaluation of primary bone and soft-tissue tumors. AJR. American Journal of Roentgenology, 146, 749–756.PubMed
36.
Mankin, H. J., Mankin, C. J., & Simon, M. A. (1996). The hazards of the biopsy, revisited: members of the Musculoskeletal Tumor Society. The Journal of bone and joint surgery, 78, 656–663.PubMed
37.
Dahlin, D. C. (1978). Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treatment Reports, 62, 189–192.PubMed
38.
Ozaki, T., Flege, S., Kevric, M., Lindner, N., Masas, R., Delling, G. S. R., et al. (2003). Osteosarcoma of the pelvic: experience of the Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 21, 334–341.PubMedCrossRef
39.
Ozaki, T., Flege, S., Liljenqvist, U., Hillmann, A., Delling, G. S. R., Salzer-Kuntschik, M., et al. (2002). Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer, 94, 1069–1077.PubMedCrossRef
40.
Magishi, K., Yoshida, H., Izumi, Y., Ishikawa, N., & Kubota, H. (2004). Primary osteosarcoma of the lung: report of a case. Surgery Today, 34, 150–152.PubMedCrossRef
41.
Bieling, P., Rehan, N., Winkler, P., Helmke, K., Maas, R., Fuchs, N., et al. (1996). Tumor size and prgonosis in sggressively treated osteosarcoma. Journal of Clinical Oncology, 14, 848–858.PubMed
42.
Wolf, R. E., & Enneking, W. F. (1996). The staging and surgery of musculoskeletal neoplasms. The Orthopedic clinics of North America, 27, 473–481.PubMed
43.
Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A., Balch, C. M., Haller, D. G., et al. (2002). AJCC cancer staging manual (6th). New York: Springer.CrossRef
44.
Meyers, P. A., & Gorlick, R. (1997). Osteosarcoma. Pediatric clinics of North America, 44, 973–989.PubMedCrossRef
45.
Bacci, G., Longhi, A., Fagioli, F., Briccoli, A., Versari, M., & Picci, P. (2005). Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 years experience at Rizzoli Institute, Italy. European Journal of Cancer, 41, 2836–2845.PubMedCrossRef
46.
Patel, S. J., Lynch, J. W. J., Johnson, T., Carroll, R. R., Schumacher, C. R. N., Spanier, S., & Scarborough, M. (2002). Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. American Journal of Clinical Oncology, 25, 489–495.PubMedCrossRef
47.
Halperin, E. C. (2005). Osteosarcoma. In E. C. Halperin, et al. (Eds.), Pediatric Radiation Oncology (pp. 291–318). Philadelphia: Williams & Wilkins.
48.
Ferguson, W. S., & Goorin, A. M. (2001). Current treatment of osteosarcoma. Cancer Investigation, 19, 292–315.PubMedCrossRef
49.
Ozaki, I., Flege, S., Lijenqvist, U., Hillmann, A., Delling, G., Salzer-Kuntschik, M., et al. (2002). Osteosarcoma of the spine: experience of the Cooperative Osteosarcom Study Group. Cancer, 94, 1069–1077.PubMedCrossRef
50.
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., et al. (2005). Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. Journal of Clinical Oncology, 23, 8845–8852.PubMedCrossRef
51.
Jaff, N., Carrasco, H., Raymond, K., Ayala, A., & Eftekhari, F. (2003). Cancure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery. Cancer, 95, 2202–2210.CrossRef
52.
Lee, E. S. (1971). Treatment of bone sarcoma. Proceedings of the Royal Society of Medicine, 64, 1179–1181.PubMed
53.
Philips, T. L., & Sheline, G. E. (1969). Radiation therapy of malignant bone tumors. Radiology, 92, 1537–1545.
54.
Machak, G. N., Tkachev, S. I., Solovyev, Y. N., Sinyukov, P. A., Ivanov, S. M., Kochergina, N. V., et al. (2003). Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clinic Proceedings, 78, 147–155.PubMedCrossRef
55.
Yamamoto, T., Akisue, T., Marui, T., Nagira, K., & Kurosaka, M. (2002). Osteosarcoma of the distal radius treated by introperative extracorporeal irradiation. Journal of the Hand Surgery, 27, 160–164.
56.
Hong, A., Stevens, G., Stalley, P., Pendlebury, S., Ahern, V., Ralston, A., et al. (2001). Extracorporeal irradiation for malignant bone tumors. International Journal of Radiation Oncology, Biology, Physics, 50(2), 441–447.PubMedCrossRef
57.
Araki, N., Myoui, A., Kuratsu, S., Hashimoto, N., Inoue, T., Kudawara, I., et al. (1999). Intraoperative extracorporeal autogenous irradiated bone graft in tumor surgery. Clinical Orthopaedics, 368, 196–206.CrossRef
58.
Gilchrist, G. S., Pritchard, D. J., & Dahlin, D. C. (1981). Management of osteogenic sarcoma: a perspective based on the Mayo Clinic experience. National Cancer Institute Monograph, 56, 193–199.PubMed
59.
Giritsky, A. S., Etucubanas, E., & Mark, J. B. (1978). Pulmonary resection in children with metastaic osteogenic sarcoma: improved survival with surgery, chemotherapy, and irradiation. The Journal of Thoracic and Cardiovascular Surgery, 75, 354–362.PubMed
60.
Weichselbaum, R. R., Cassady, J. R., & Jaffe, N. (1977). Preliminary results of aggressive multimodality therapy for metastatic osteosarcoma. Cancer, 40, 78–83.PubMedCrossRef
61.
Picci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., et al. (1985). Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer, 56, 1515–1521.PubMedCrossRef
62.
Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987). Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. Journal of Cancer and Clinical Oncology, 5, 21–26.
63.
Link, M. P., Goorin, A. M., Horowitz, M., Meyer, W. H., Belasco, J., Baker, A., et al. (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clinical orthopaedics, 270, 8–14.
64.
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., et al. (1982). Preoperative chemotherapy of osteosarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to the preoperative therapy. Cancer, 49, 1221–1230.PubMedCrossRef
65.
Hudson, M., Jaffe, M. R., Jaffe, N., Ayala, A., Raymond, A. K., Carrasco, H., et al. (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. Journal of Clinical Oncology, 12, 1988–1997.
66.
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., et al. (1997). Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. Journal of Clinical Oncology, 15, 76–84.PubMed
67.
Man, T.-K., Chintagumpala, M., Visvanathan, J., Shen, J., Perlaky, L., Hicks, J., et al. (2005). Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy. Cancer Research, 65, 8142–8150.PubMedCrossRef
68.
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., et al. (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 350, 911–917.PubMedCrossRef
69.
Ferrari, S., & Palmerini, E. (2007). Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Current Opinion in Oncology, 19, 341–346.PubMedCrossRef
70.
Fuchs, N., Bielack, S. S., Epler, D., Biding, P., Delling, G., Körholz, D., et al. (1998). Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Annals of Oncology, 9, 893–899.PubMedCrossRef
71.
Petrilli, A. S., de Camargo, B., Filho, V. O., Bruniera, P., Brunetto, A. L., Jesus-Garcia, R., et al. (2006). Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. Journal of Clinical Oncology, 24, 1161–1168.PubMedCrossRef
72.
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Kleinerman, E. S., Betcher, D., Bernstein, M. L., et al. (2005). Osteosarcoma: a randomized prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate. Journal of Clinical Oncology, 23, 2004–2011.PubMedCrossRef
73.
Eselgrim, M., Grunert, H., Kuhne, T., Zoubek, A., Kevric, M., Bürger, H., et al. (2006). Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trial. Pediatric Blood and Cancer, 47, 42–50.PubMedCrossRef
74.
Lewis, I. J., Weeden, S., Machin, D., Stark, D., & Craft, A. W. (2000). Received dose and dose intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. Journal of Clinical Oncology, 18, 4028–4037.PubMed
75.
Daw, N. C., Billups, C. A., Rodriguez-Galindo, C., McCarville, M. B., Rao, B. N., Cain, A. M., et al. (2006). Metastatic osteosarcoma. Cancer, 106, 403–412.PubMedCrossRef
76.
Bacci, G., Fabbri, N., Balladelli, A., Forni, C., Palmerini, E., & Picci, P. (2006). Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. Journal of Bone and Joint Surgery American, 88, 1071–1075.CrossRef
77.
Kager, L., Zoubek, A., Kastner, U., Kempf-Bielack, B., Potratz, J., Kotz, R., et al. (2006). Skip metastases in osteosarcoma : Experience of The Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 24, 1535–1541.PubMedCrossRef
78.
Ek, E. T. H., Dass, C. R., Contreras, K. G., & Choong, P. F. M. (2007). Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Therapy, 14, 616–626.PubMedCrossRef
79.
Okuno, S. (2006). Mammalian target of rapamycin inhibitors in sarcomas. Current Opinion in Oncology, 18, 360–362.PubMedCrossRef
80.
Kubo, T., Shimose, S., Matsuo, T., Tanaka, K., Yasunaga, Y., Sakai, A., et al. (2006). Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. Journal of Orthopaedic Research, 24, 1138–1144.PubMedCrossRef
81.
Murayama, T., Kawasoe, Y., Yamashita, Y., Ueno, Y., Minami, S., Yokouchi, M., et al. (2008). Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Reseach, 28, 2147–2154.
82.
Kubista, B., Trieb, K., Sevelda, F., Toma, C., Arrich, F., Heffeter, P., et al. (2006). Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of Orthopaedic Research, 24, 1145–1152.PubMedCrossRef
83.
Horie, N., Murata, H., Kimura, S., Takeshita, H., Sakabe, T., Matsui, T., et al. (2007). Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. British Journal of Cancer, 96, 255–261.PubMedCrossRef
84.
Benassi, M., Chiechi, A., Ponticelli, F., Pazzaglia, L., Gamberi, G., Zanella, L., et al. (2006). Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters, 250, 194–205.PubMedCrossRef
85.
Tomlin, J. L., Pead, M. J., & Muir, P. (2000). Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. The Veterinary Record, 147, 129–132.PubMed
86.
Kotz, R., Plattner, E., Ramach, W., Flener, R., & Bodo, G. (1982). Interferon/controlled study in 3-year survival of patients with recurrent osteosarcoma. Arzneimittelforschung, 32, 446–448.PubMed
87.
Müller, C. R., Smeland, S., Bauer, H. C., Saeter, G., & Strander, H. (2005). Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncologica, 44, 475–480.PubMedCrossRef
88.
Strander, H., Aparisi, T., Blomgren, H., Broström, L. A., Cantell, K., Einhorn, S., et al. (1982). Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Research, 80, 103–107.
89.
Strander, H., Bauer, H. C., Brosjö, O., Kreicbergs, A., Lindholm, J., Nilsonne, U., et al. (1993). Adjuvant interferon treatment in human osteosarcoma. Cancer Treatment and Research, 62, 29–32.PubMed
90.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., et al. (2004). Adjuvant chemotherapy in osteosarcoma—Effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Journal of Cancer Research and Clinical Oncology, 106, 1–7.CrossRef
91.
Stanton, G. J., Weigent, D. A., Fleischmann, W. R. J., Dianzani, F., & Baron, S. (1987). Interferon review. Investigative Radiology, 22, 259–273.PubMedCrossRef
92.
Jonasch, E., & Haluska, F. G. (2001). Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist, 1, 34–55.CrossRef
93.
Strander, H. (1989). The action of interferon on virus-associated human neoplasms. Cancer Surveys, 8, 755–792.PubMed
94.
Glasgow, L. A., Crane, J. L. Jr., Kern, E. R., & Youngner, J. S. (1978). Antitumor activity of interferon angainst murine osteogenic sarcoma in vitro and in vivo. Cancer Treatment Reports, 62, 1881–1888.PubMed
95.
Glasgow, L. A., & Kern, E. R. (1981). Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. Journal of the National Cancer Institute, 67, 207–212.PubMed
96.
Jia, S. F., An, T., Worth, L., & Kleinerman, E. S. (1999). Interferon-alpha Enhances the Sensitivity of Human Osteosarcoma Cells to Etoposide. Journal of Interferon and Cytokine Research, 19, 617–624.PubMedCrossRef
97.
Yuan, X.-w., Zhu, X.-f., Huang, X.-f., Sheng, P.-y., He, A.-s., Yang, Z.-b., et al. (2007). Interferon-a enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacologica Sinica, 28, 1835–1841.PubMedCrossRef
98.
Inaba, H., Glibetic, M., Buck, S., Ravindranath, Y., & Kaplan, J. (2004). Interferon-alpha sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8. Pediatrica Blood Cancer, 43, 729–736.CrossRef
99.
Waldmann, T. A. (2006). The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature reviews. Immunology, 6, 595–601.PubMedCrossRef
100.
Waldmann, T. A., & Tagaya, Y. (1999). The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annual Review of Immunology, 17, 19–49.PubMedCrossRef
101.
Luksch, R., Perotti, D., Cefalo, G., Gambacorti Passerini, C., Massimino, M., Spreafico, F., et al. (2003). Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumorigenesis, 89, 263–268.
102.
Schwartz, Y., Avraham, R., Benish, M., Rosenne, E., & Ben-Eliyahu, S. (2008). Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Research and Treatment, 107, 211–223.PubMedCrossRef
103.
Nardin, A., Lefebvre, M. L., Labroquere, K., Faure, O., & Abastado, J. P. (2006). Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Current Cancer Drug Targets, 6, 123–133.PubMedCrossRef
104.
Chawla, S. P., Tolcher, A. W., Staddon, A. P., Schuetze, S. M., D’Amato, G. Z., Blay, J. Y., et al. (2006). Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas (Abstract). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I., 24 (June 20 Supplement), Abstract 9505.
105.
Quan, G. M. Y., & Choong, P. F. M. (2006). Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Review, 25, 707–713.CrossRef
106.
Folkman, J. (2004). Endogenous angiogenesis inhibitors. Acta pathologica, microbiologica, immunologica Scandinavica, 112, 496–507.
107.
Tjin Tham Sjin, R. M., Naspinski, J., Birsner, A. E., Li, C., Chan, R., Lo, K. M., et al. (2006). Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Therapy, 13, 619–627.PubMedCrossRef
108.
Mohammed, R. A., Green, A., El-Shikh, S., Paish, E. C., Ellis, I. O., & Martin, S. G. (2007). Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. British Journal of Cancer, 96, 1092–1100.PubMedCrossRef
109.
Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6, 572–577.PubMed
110.
Hara, H., Akisue, T., Fujimoto, T., Imabori, M., Kawamoto, T., Kuroda, R., et al. (2006). Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Research, 26, 4307–4311.PubMed
111.
Mantadakis, E., Kim, G., Reisch, J., McHard, K., Maale, G., Leavey, P. J., et al. (2001). Lack of prognostic significance of intratumoral angiogenesis in non metastatic osteosarcoma. Journal of Pediatric Hematology/Oncology, 23, 286–289.PubMedCrossRef
112.
Ek, E. T. H., Ojaimi, J., Kitagawa, Y., & Choong, P. F. M. (2006). Does the degree of intratumoral microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncology Reports, 16, 17–23.PubMed
113.
Kreuter, M., Bieker, R., Bielack, S. S., Auras, T., Buerger, H., Gosheger, G., et al. (2004). Prognostic relevance of increased angiogenesis in osteosarcoma. Clinical Cancer Research, 10, 8531–8537.PubMedCrossRef
114.
Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., & Benedict, W. (1999). Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 285, 245–248.PubMedCrossRef
115.
Volpert, O. V., Zaichuk, T., Zhou, W., Reiher, F., Ferguson, T. A., & Stuart, P. M. (2002). Inducer-stimulated Fas targets activates endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nature Medicine, 8, 349–357.PubMedCrossRef
116.
Cai, J., Jiang, W. G., Grant, M. B., & Boulton, M. (2006). Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of VEGFR-1. Journal of biological chemistry, 281, 3604–3613.PubMedCrossRef
117.
Pignolo, R. J., Francis, M. K., Rotenberg, M. O., & Cristofalo, V. J. (2003). Putative role for EPC-1/PEDF in the growth arrest of human diploid fibroblasts. Journal of cellular physiology, 195, 12–20.PubMedCrossRef
118.
Abe, R., Shimizu, T., Yamagishi, S., Shibaki, A., Amano, S., & Inagaki, Y. (2004). Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. The American Journal of Pathology, 164, 1225–1232.PubMed
119.
Foukas, A. F., Deshmukh, N. S., Grimer, R. J., Mangham, D. C., Mangos, E. G., & Taylor, S. (2002). Stage-IIB osteosarcoma around the knee. A study of MMP-9 in surviving tumour cells. The Journal of Bone and Joint Surgery, British volume, 84, 706–711.CrossRef
120.
Vinodhkumar, R., Song, Y. S., Ravikumar, V., Ramakrishnan, G., & Devaki, T. (2007). Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chemico-Biological Interactions, 165, 220–229.PubMedCrossRef
121.
Shin, C. Y., Lee, W. J., Choi, J. W., Choi, M. S., Ryu, J. R., Oh, S. J., et al. (2007). Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide, 16, 425–432.PubMedCrossRef
122.
Kang, H. G., Kim, H. S., Kim, K. J., Oh, J. H., Lee, M. R., Seol, S. M., et al. (2007). RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. Journal of Orthopaedic Research, 25, 696–702.PubMedCrossRef
123.
Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., et al. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America, 95, 13221–13226.PubMedCrossRef
124.
Oh, J. H., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., et al. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell, 107, 789–800.PubMedCrossRef
125.
Choong, P. F. M., & Nadesapillai, A. P. W. (2003). Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clinical orthopaedics and related research, 415(Suppl), S46–S58.PubMedCrossRef
126.
Choong, P. F. M., Ferno, M., Akerman, M., Willen, H., Langstrom, E., Gustafson, P., et al. (1996). Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. International Journal of Cancer, 69, 268–273.CrossRef
127.
Dass, C. R., Nadesapillai, A. P. W., Robin, D., Howard, M. L., Fisher, J. L., Zhou, H., et al. (2005). Downregulation of uPAR cofirms link in growth and metatasis of osteosarcoma. Clinical and Experimental Metastasis, 22, 643–652.PubMedCrossRef
128.
Dass, C. R., & Choong, P. F. M. (2008). uPAR mediates anticancer activity of PEDF. Cancer Biology and Therapy, 7, 1262–1270.PubMedCrossRef
129.
Baldini, N., Scotlandi, K., Serra, M., Picci, P., Bacci, G., Sottili, S., et al. (1999). P-glycoprotein expression in osteosarcoma: a basic for risk-adapted adjuvant chemotherapy. Journal of Orthopaedic Research, 17, 629–632.PubMedCrossRef
130.
Chan, H. S., Grogan, T. M., Haddad, G., DeBoer, G., & Ling, V. (1997). P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. Journal of the National Cancer Institute, 89, 1706–1715.PubMedCrossRef
131.
Laverdiere, C., Hoang, B. H., Yang, R., Sowers, R., Qin, J., Meyers, P. A., et al. (2005). Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clinical Cancer Research, 11, 2561–2567.PubMedCrossRef
132.
Perissinotto, E., Cavalloni, G., Leone, F., Fonsato, V., Mitola, S., Grignani, G., et al. (2005). Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clinical Cancer Research, 11(2 Pt 1), 490–497.PubMed
133.
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. Journal of Molecular Medicine, 85, 1175–1186.PubMedCrossRef
134.
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koeffler, H. P. (1996). Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Journal of Cancer Research and Clinical Oncology, 122, 559–565.PubMedCrossRef
135.
McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassel, J., Borresen, A. L., Yan, Y. X., et al. (1994). Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. Journal Clinical Oncology, 12, 925–930.
136.
Nakase, M., Inui, M., Okumura, K., Kamei, T., Nakamura, S., & Tagawa, T. (2005). p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Molecular Cancer Therapeutics, 4, 625–631.PubMedCrossRef
137.
Densmore, C. L., Kleinerman, E. S., Gautam, A., Jia, S.-F., Xu, B., Worth, L. L., et al. (2001). Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Therapy, 8, 619–627.PubMedCrossRef
138.
Onda, M., Matsuda, S., Higaki, S., Ijima, T., Fukushima, J., Yokokura, A., et al. (1996). ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer, 77, 71–78.PubMedCrossRef
139.
Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T., Coffin, C. M., & Goldsby, R. E. (2003). Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. Journal of Pediatric Hematology/Oncology, 25, 27–32.PubMedCrossRef
140.
141.
Hunter, K. W. (2004). Ezrin, a key component in tumor metastasis. Trends in Molecular Medicine, 10, 201–204.PubMedCrossRef
142.
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., et al. (2004). The membrane-cyto-skeleton linker ezrin is necessary for osteosarcoma metastasis. Nature Medicine, 10, 182–186.PubMedCrossRef
143.
Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005). Rapamycin inhibits ezrin-mediated metastatic behaviour in a murine model of osteosarcoma. Cancer Research, 65, 2406–2411.PubMedCrossRef
144.
Pasquini, G. M., Davey, R. A., Ho, P. W., Michelangeli, V. P., Grill, V., Kaczmarczyk, S. J., & Zajac, J. D. (2002). Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106–01) cell line results in growth inhibition. Bone, 31, 598–605.PubMedCrossRef
145.
Yang, R., Hoang, B. H., Kubo, T., Kawano, H., Chou, A., Sowers, R., et al. (2007). Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. International Journal of Cancer, 121, 943–954.CrossRef
146.
Dass, C. R., & Choong, P. F. (2008). C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies. Pharmazie, 63, 411–414.PubMed
147.
Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., & Tjian, R. (1987). Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science, 238, 1386–1392.PubMedCrossRef
148.
Dass, C. R., Khachigian, L. M., & Choong, P. F. M. (2008). c-Jun is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Molecular Cancer Research, 6, 1289–1292.PubMedCrossRef
149.
Dass, C. R., Friedhuber, A. M., Khachigian, L. M., Dunstan, D. E., & Choong, P. F. (2008). Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer biology & therapy, 7, 1033–1036.CrossRef
150.
Dass, C. R., Friedhuber, A. M., Khachigian, L. M., Dunstan, D. E., & Choong, P. F. (2008). Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. Journal of Microencapsulation, 25, 421–425.PubMedCrossRef
151.
Dass, C. R., Khachigian, L. M., & Choong, P. F. M. (2008). c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Molecular Cancer Therapeutics, 7, 1909–1912.PubMedCrossRef
152.
MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R., Kurzman, I. D., Thamm, D. H., et al. (2004). IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. Journal of Cellular Biochemistry, 92, 77–91.PubMedCrossRef
153.
Sekyi-Otu, A., Bell, R. S., Ohashi, C., Pollak, M., & Andrulis, I. L. (1995). Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Research, 55, 129–134.PubMed
154.
Pollak, M., Sem, A. W., Richard, M., Tetenes, E., & Bell, R. (1992). Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute, 84, 966–971.PubMedCrossRef
155.
Burrow, S., Andrulis, I. L., Pollak, M., & Bell, R. S. (1998). Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. Journal of Surgical Oncology, 69, 21–27.PubMedCrossRef
156.
157.
Pollak, M., Sem, A. W., Richard, M., Tetenes, E., & Bell, R. (1992). Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute, 84, 966–971.PubMedCrossRef
158.
Mansky, P. J., Liewehr, D. J., Steinberg, S. M., Chrousos, G. P., Avila, N. A., Long, L., et al. (2002). Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. Journal of Pediatric Hematology/Oncology, 24, 440–446.PubMedCrossRef
Metadata
Title
Osteosarcoma treatment: state of the art
Authors
Hang T. Ta
Crispin R. Dass
Peter F. M. Choong
Dave E. Dunstan
Publication date
01-06-2009
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-009-9186-7

Other articles of this Issue 1-2/2009

Cancer and Metastasis Reviews 1-2/2009 Go to the issue

NON-THEMATIC REVIEW

Emerging role of nuclear protein 1 (NUPR1) in cancer biology

OriginalPaper

Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix

OriginalPaper

The cytoskeleton and cancer

OriginalPaper

EMT, the cytoskeleton, and cancer cell invasion

OriginalPaper

Kinesin motor proteins as targets for cancer therapy

NON-THEMATIC REVIEW

The unfolded protein response during prostate cancer development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits